This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wallace, R J
Right arrow Articles by Graham, D R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wallace, R J, Jr
Right arrow Articles by Graham, D R

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1990 January; 34(1): 65-70

Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy.

R J Wallace Jr, G Bedsole, G Sumter, C V Sanders, L C Steele, B A Brown, J Smith and D R Graham

Department of Microbiology, University of Texas Health Center, Tyler 75710.

ABSTRACT

The susceptibility to ciprofloxacin of 548 clinical isolates of rapidly growing mycobacteria belonging to eight subgroups or species was determined. The 170 isolates of Mycobacterium fortuitum biovar.fortuitum were most susceptible; the MIC for 90% of the organisms was 0.125 micrograms/ml. The other biovariants of M. fortuitum, M. smegmatis, and the M. chelonae-like organisms were less susceptible; the modal MIC was 0.5 micrograms/ml, and the MIC for 90% of organisms was 1.0 micrograms/ml. The two subspecies of M. chelonae were generally resistant, with only 8% of 206 isolates falling in the moderately susceptible category (MIC, 2 micrograms/ml) and only 2% falling in the susceptible category (MIC, less than or equal to 1 micrograms/ml). MICs of ofloxacin averaged 1 to 2 dilutions higher than those of ciprofloxacin for all subgroups tested. Three patients with M. fortuitum cutaneous disease relapsed after an initial response to therapy with ciprofloxacin, and their isolate was shown to have acquired drug resistance. Mutational frequencies for M. fortuitum with ciprofloxacin were relatively high (10(-5) to 10(-7), and MICs for single-step mutants were similar to those for the clinically resistant strains. Thus, despite the excellent activity of ciprofloxacin against rapidly growing mycobacterial groups other than M. chelonae, single-drug therapy should be used with caution because of the risk of development of mutational resistance.

Antimicrob Agents Chemother. 1990 January; 34(1): 65-70




This article has been cited by other articles:

  • Umubyeyi, A. N., Rigouts, L., Shamputa, I. C., Fissette, K., Elkrim, Y., de Rijk, P. W. B., Struelens, M. J., Portaels, F. (2007). Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national survey. J Antimicrob Chemother 59: 1031-1033 [Abstract] [Full Text]  
  • Uslan, D. Z., Kowalski, T. J., Wengenack, N. L., Virk, A., Wilson, J. W. (2006). Skin and Soft Tissue Infections Due to Rapidly Growing Mycobacteria: Comparison of Clinical Features, Treatment, and Susceptibility.. Arch Dermatol 142: 1287-1292 [Abstract] [Full Text]  
  • Adekambi, T., Berger, P., Raoult, D., Drancourt, M. (2006). rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov.. Int. J. Syst. Evol. Microbiol. 56: 133-143 [Abstract] [Full Text]  
  • Wallace, R. J. Jr., Brown-Elliott, B. A., Brown, J., Steigerwalt, A. G., Hall, L., Woods, G., Cloud, J., Mann, L., Wilson, R., Crist, C., Jost, K. C. Jr., Byrer, D. E., Tang, J., Cooper, J., Stamenova, E., Campbell, B., Wolfe, J., Turenne, C. (2005). Polyphasic Characterization Reveals that the Human Pathogen Mycobacterium peregrinum Type II Belongs to the Bovine Pathogen Species Mycobacterium senegalense. J. Clin. Microbiol. 43: 5925-5935 [Abstract] [Full Text]  
  • Sniezek, P. J., Graham, B. S., Busch, H. B., Lederman, E. R., Lim, M. L., Poggemyer, K., Kao, A., Mizrahi, M., Washabaugh, G., Yakrus, M., Winthrop, K. (2003). Rapidly Growing Mycobacterial Infections After Pedicures. Arch Dermatol 139: 629-634 [Abstract] [Full Text]  
  • Brown-Elliott, B. A., Wallace, R. J. Jr. (2002). Clinical and Taxonomic Status of Pathogenic Nonpigmented or Late-Pigmenting Rapidly Growing Mycobacteria. Clin. Microbiol. Rev. 15: 716-746 [Abstract] [Full Text]  
  • Brown-Elliott, B. A., Wallace, R. J. Jr., Crist, C. J., Mann, L., Wilson, R. W. (2002). Comparison of In Vitro Activities of Gatifloxacin and Ciprofloxacin against Four Taxa of Rapidly Growing Mycobacteria. Antimicrob. Agents Chemother. 46: 3283-3285 [Abstract] [Full Text]  
  • Wallace, R. J. Jr., Brown-Elliott, B. A., Hall, L., Roberts, G., Wilson, R. W., Mann, L. B., Crist, C. J., Chiu, S. H., Dunlap, R., Garcia, M. J., Bagwell, J. T., Jost, K. C. Jr. (2002). Clinical and Laboratory Features of Mycobacterium mageritense. J. Clin. Microbiol. 40: 2930-2935 [Abstract] [Full Text]  
  • Valera, L., Gradelski, E., Huczko, E., Washo, T., Yigit, H., Fung-Tomc, J. (2002). In vitro activity of a novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), against rapidly growing mycobacteria and Nocardia isolates. J Antimicrob Chemother 50: 140-142 [Full Text]  
  • Wallace, R. J. Jr., Brown-Elliott, B. A., Ward, S. C., Crist, C. J., Mann, L. B., Wilson, R. W. (2001). Activities of Linezolid against Rapidly Growing Mycobacteria. Antimicrob. Agents Chemother. 45: 764-767 [Abstract] [Full Text]  
  • Margo, C. E., Pavan, P. R. (2000). Mycobacterium chelonae Conjunctivitis and Scleritis Following Vitrectomy. Arch Ophthalmol 118: 1125-1128 [Abstract] [Full Text]  
  • Subcommittee of the Joint Tuberculosis Committee o, (2000). Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999. Thorax 55: 210-218 [Full Text]  
  • Fernández-Roblas, R., Esteban, J., Cabria, F., López, J. C., Jiménez, M. S., Soriano, F. (2000). In Vitro Susceptibilities of Rapidly Growing Mycobacteria to Telithromycin (HMR 3647) and Seven Other Antimicrobials. Antimicrob. Agents Chemother. 44: 181-182 [Abstract] [Full Text]  
  • Patel, J. B., Leonard, D. G. B., Pan, X., Musser, J. M., Berman, R. E., Nachamkin, I. (2000). Sequence-Based Identification of Mycobacterium Species Using the MicroSeq 500 16S rDNA Bacterial Identification System. J. Clin. Microbiol. 38: 246-251 [Abstract] [Full Text]  
  • Woods, G. L., Bergmann, J. S., Witebsky, F. G., Fahle, G. A., Wanger, A., Boulet, B., Plaunt, M., Brown, B. A., Wallace, R. J. Jr. (1999). Multisite Reproducibility of Results Obtained by the Broth Microdilution Method for Susceptibility Testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J. Clin. Microbiol. 37: 1676-1682 [Abstract] [Full Text]  
  • Guillemin, I., Jarlier, V., Cambau, E. (1998). Correlation between Quinolone Susceptibility Patterns and Sequences in the A and B Subunits of DNA Gyrase in Mycobacteria. Antimicrob. Agents Chemother. 42: 2084-2088 [Abstract] [Full Text]  
  • Wallace, R. J., Tanner, D., Brennan, P. J., Brown, B. A. (1993). Clinical Trial of Clarithromycin for Cutaneous (Disseminated) Infection due to Mycobacterium chelonae. ANN INTERN MED 119: 482-486 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»